Here’s What the Street is Saying About Alphatec Holdings (ATEC) Post Earnings

Alphatec Holdings, Inc. (NASDAQ:ATEC) is one of the best healthcare stocks to buy for the long term. Alphatec Holdings, Inc. (NASDAQ:ATEC) received several rating updates following the release of its fiscal Q1 2026 results on May 5, with surgical revenue growing 17% and total revenue growing 14%. Canaccord cut the price target on the stock to $23 from $25 on May 7, but maintained a Buy rating on the shares, stating that the company posted an uncharacteristic miss in the quarter with its EOS business declining 18% year over year. It added that Alphatec Holdings’ (NASDAQ:ATEC) surgical business was more in line with expectations, with 21% case volume growth and 23% net new surgeon growth, but another quarter of weak rev/case growth against shifting regional/procedural/biologics mix.

The same day, Piper Sandler also cut the price target on Alphatec Holdings, Inc. (NASDAQ:ATEC), bringing it down to $14 from $25 while maintaining an Overweight rating on the shares. The firm was of the view that the company reported fiscal Q1 results below expectations, driven by a disappointing EOS quarter and softer-than-expected revenue per case on mix headwinds.

Alphatec Holdings, Inc. (NASDAQ:ATEC) designs, develops, and markets spinal fusion technology products and solutions to treat spinal disorders. The company’s offerings include intra-operative information and neuromonitoring technologies, fixation systems, access systems, interbody implants, and various biologics offerings.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.